SMW Free Realtime Trade Alerts -- Our Last 2 Trade Alerts were VII and NFEC, easy 40-75% wins in minutes, Join Today for FREE!!
Geron Corporation(NASDAQ : GERN)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Loading GERN News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.79%||86.55||1.6%||$778.69m|
|REGN||Regeneron Pharmaceuticals, Inc.||0.47%||391.34||3.1%||$323.98m|
|ALXN||Alexion Pharmaceuticals, Inc.||-1.18%||125.80||2.6%||$289.82m|
|BMRN||BioMarin Pharmaceutical Inc.||0.24%||93.58||3.9%||$197.30m|
|VRTX||Vertex Pharmaceuticals Incorporated||0.73%||93.89||1.7%||$132.65m|
|JUNO||Juno Therapeutics, Inc.||1.04%||29.13||7.9%||$106.11m|
|A||Agilent Technologies, Inc.||-0.21%||46.57||1.9%||$100.85m|
|ACAD||ACADIA Pharmaceuticals Inc.||1.36%||36.55||13.1%||$79.16m|
Geron Corp. discovers and develops therapeutic products for cancer. It is a clinical stage biopharmaceutical company developing a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company's imetelstat, their sole product candidate, is a potent and specific inhibitor of telomerase. Based on clinical data, they may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, which includes patients with primary MF, post-essential thrombocythemia MF, myelodysplastic syndromes, acute myelogenous leukemia. Geron was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.